Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig L Slingluff

Showing results (111-120 of 226) with videos related to

Pageof 23
Sort By:
Cancer Research|January 24, 2012
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanomaGulsun Erdag, Jochen T Schaefer, Mark E Smolkin, et al.
Journal of Translational Medicine|September 20, 2013
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and BevacizumabAubrey G Wagenseller, Amber Shada, Kevin M D'Auria, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2013
Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptideElise P Salerno, Sofia M Shea, Walter C Olson, et al.
Nature Communications|March 23, 2024
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trialEmily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock, et al.
Nature Communications|September 5, 2025
Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trialEmily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Interferons induce CXCR3-cognate chemokine production by human metastatic melanomaLynn T Dengel, Allison G Norrod, Briana L Gregory, et al.
Journal of Surgical Oncology|March 31, 2021
Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancerKevin T Lynch, William J Kane, Mark A Fleming, et al.
Annals of Surgery|December 20, 2022
A Step Toward Personalized Surgical Decision Making: Machine Learning Predicts 1 Versus Numerous Melanoma Lymph Node Metastases Using RNA-sequencingMax O Meneveau, Rick D Vavolizza, Anwaruddin Mohammad, et al.
Journal of Translational Medicine|March 10, 2011
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic functionWalter C Olson, Mark E Smolkin, Erin M Farris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineCraig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Pageof 23

Showing results (111-120 of 226) with videos related to

Sort By:
Pageof 23
Cancer Research|January 24, 2012
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanomaGulsun Erdag, Jochen T Schaefer, Mark E Smolkin, et al.
Journal of Translational Medicine|September 20, 2013
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and BevacizumabAubrey G Wagenseller, Amber Shada, Kevin M D'Auria, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2013
Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptideElise P Salerno, Sofia M Shea, Walter C Olson, et al.
Nature Communications|March 23, 2024
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trialEmily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock, et al.
Nature Communications|September 5, 2025
Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trialEmily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Interferons induce CXCR3-cognate chemokine production by human metastatic melanomaLynn T Dengel, Allison G Norrod, Briana L Gregory, et al.
Journal of Surgical Oncology|March 31, 2021
Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancerKevin T Lynch, William J Kane, Mark A Fleming, et al.
Annals of Surgery|December 20, 2022
A Step Toward Personalized Surgical Decision Making: Machine Learning Predicts 1 Versus Numerous Melanoma Lymph Node Metastases Using RNA-sequencingMax O Meneveau, Rick D Vavolizza, Anwaruddin Mohammad, et al.
Journal of Translational Medicine|March 10, 2011
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic functionWalter C Olson, Mark E Smolkin, Erin M Farris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineCraig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Pageof 23